[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»Image left, text right» _builder_version=»4.16″ custom_padding=»0|0px|0px|0px|false|false» locked=»off» global_colors_info=»{}»][et_pb_row column_structure=»1_2,1_2″ use_custom_gutter=»on» custom_padding_last_edited=»on|tablet» padding_top_bottom_link_2=»true» padding_left_right_link_2=»false» _builder_version=»4.16″ width=»100%» width_tablet=»80%» width_phone=»80%» width_last_edited=»on|tablet» max_width=»100%» max_width_tablet=»80%» max_width_phone=»80%» max_width_last_edited=»on|tablet» module_alignment=»left» min_height=»677.7px» custom_margin=»|auto|-83px|auto|false|» custom_padding=»0|12%|0px|0px|false|false» custom_padding_tablet=»|0%||» custom_padding_phone=»» module_alignment_tablet=»center» module_alignment_phone=»center» module_alignment_last_edited=»on|tablet» use_custom_width=»on» width_unit=»off» custom_width_percent=»100%» locked=»off» global_colors_info=»{}»][et_pb_column type=»1_2″ _builder_version=»4.16″ custom_padding=»|||» global_colors_info=»{}» custom_padding__hover=»|||»][et_pb_image src=»https:\/\/www.chameleon-pharma.com\/wp-content\/uploads\/sebastian-pena-lambarri-Ke8EuI2xOUc-unsplash-scaled.jpg» alt=»Green Rice field in Indonesia» title_text=»Rice Field Indonesia» show_bottom_space=»off» force_fullwidth=»on» align_tablet=»center» align_phone=»center» align_last_edited=»on|desktop» _builder_version=»4.16″ background_color_gradient_direction=»90deg» background_color_gradient_start=»#404451″ background_color_gradient_end=»rgba(240,242,246,0)» custom_padding=»||||false|false» custom_padding_tablet=»||60px|» custom_padding_phone=»||10px||false|false» custom_padding_last_edited=»on|phone» animation_style=»slide» animation_direction=»left» animation_intensity_slide=»1%» global_colors_info=»{}»][\/et_pb_image][et_pb_text _builder_version=»4.16″ _module_preset=»default» text_font_size=»13px» custom_padding=»|||60px||» global_colors_info=»{}»]<\/p>\n
Featured image: Photo by Sebastian Pena Lambarri<\/a> on Unsplash<\/a><\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=»1_2″ _builder_version=»4.16″ custom_padding=»6vw||6vw|» custom_padding_tablet=»0px|0px|0px|0px|false|true» custom_padding_phone=»||||false|false» custom_padding_last_edited=»on|tablet» global_colors_info=»{}» padding_phone=»||||false|false» padding_tablet=»|10%||10%|false|true» padding_last_edited=»on|tablet» custom_padding__hover=»|||»][et_pb_text _builder_version=»4.17.4″ text_font=»||||||||» header_font=»||||||||» header_3_text_color=»#3550a0″ header_6_font=»||||||||» max_width=»942px» custom_margin=»-60px|||||» custom_padding=»0px|0px||0px||» header_3_font_size_tablet=»» header_3_font_size_phone=»20px» header_3_font_size_last_edited=»on|desktop» locked=»off» global_colors_info=»{}»]<\/p>\n All indicators are green for the Indonesian Self-Medication and Prescription Drugs market. Continue reading to find out about the opportunities this market has to offer.\u00a0<\/span><\/i><\/p>\n Indonesia is the <\/span>fourth most populous<\/b> country in the world with 277 mio. inhabitants, and its gross domestic product (GDP) has been growing in recent years. Three percent of Indonesia\u2019s GDP is spent on healthcare, and pharmaceutical spending per capita is increasing rapidly. Indonesia has almost ten thousand primary care centers and more than two thousand hospitals. <\/span>The Indonesian OTC & Pharma is expanding rapidly and should reach USD 18,409 Billion ex-factory in <\/b>2040<\/b>.<\/b><\/p>\n In order to register a drug in Indonesia, applications go to the<\/span> National Agency of Drug and Food Control (NADFC)<\/b>. The Association of Southeast Asian Nations (ASEAN) Common Technical Documents (CTD) must be used, and ASEAN standards should be followed. It can take up to <\/span>2-3 years<\/b> for a pharmaceutical product to be registered in Indonesia, but the government implemented new regulations in 2016 to simplify the process in the next few years.\u00a0<\/span><\/p>\n Over the last few years, the government of Indonesia has passed laws to <\/span>improve its healthcare infrastructure and increase public spending on healthcare. <\/b>At the beginning of 2014, Indonesia introduced a universal healthcare system, administered by the National Social Security Agency. The universal healthcare scheme aims to provide better regulations, access, cost effectiveness and standards. 86%<\/span> of the population was enrolled into the NHI scheme by the beginning of 2022<\/b>.\u00a0<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=»4.17.4″ _module_preset=»default» custom_padding=»0px|||||» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.17.4″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.17.4″ _module_preset=»default» header_3_text_color=»#001389″ global_colors_info=»{}»]<\/p>\n The main obstacles to big investments in Indonesia\u2019s OTC and pharma industry are corruption, low cost per capita for health care services and a relatively small percentage of elderly residents. However, this percentage is rising and the very large young population represents a significant target consumer base for children\u2019s products.<\/span><\/p>\n Several Indonesian laws protect the local industry from foreign competition. One of the decrees adopted in 2008 requires that all pharmaceuticals registered in the country be <\/span>locally produced<\/b>. This law was <\/span>eased in 2010<\/b>, allowing labeling and packaging to meet the local manufacturing standard. Foreign OTC and pharma companies have reacted to this decree by partnering with domestic companies or other international companies, or by expanding their own local manufacturing capacities in Indonesia.<\/span><\/p>\n As a part of measures for increasing the capacity of the national Consumer Health and Pharma market, the Pharmaceutical Association of Indonesia (GP Farmasi) announced that the domestic Healthcare sector relies on the creation of factories owned by foreign companies within the country. At the same time, active cooperation with OTC and Pharma companies of the Association of Southeast Asian Nations (ASEAN) is assumed. The <\/span>goal <\/b>is to create an <\/span>industrial base of pharmaceutical raw materials in Indonesia<\/b>. The data collected by GP Farmasi shows that the market for Selfmedication and Pharma products in the ASEAN region is rising.<\/span><\/p>\n At the same time, the National AIDS Commission has said that to ensure a steady supply of antiretroviral drugs to patients with AIDS, Indonesia will continue to receive donations in the form of drugs rather than cash. This new rule was approved by the <\/span>Global Fund for AIDS<\/b>, <\/span>Tuberculosis <\/b>and <\/span>Malaria<\/b>. The Indonesian Ministry of Health has also allocated money to develop solutions and treatments against AIDS.\u00a0<\/span><\/p>\n However, despite the above-mentioned challenges, the Indonesian consumer health and pharma market still provides a significant <\/span>opportunity for foreign self-medication and prescription companies<\/b>. Factors such as the annual growth of the Indonesian pharma market, along with the increase in population and relatively solid economic and political base, should ensure the continued involvement of multinational pharmaceutical companies. Analysts believe that sales of pharmaceutical products in Indonesia will continue to increase over the next 10 years.<\/span><\/p>\n \u00a0<\/span><\/p>\n If you are planning on entering the Indonesian OTC and pharma market, our expertise and long standing network can support you. Chameleon Pharma Consulting Group\u2019s knowledge of the Indonesian consumer healthcare and pharma market is based on multiple Indonesian projects over the past 15 years. All our experts have at least 20 years experience, and we have supported several leading European and international companies in entering the Health care, Medical devices and prescription sectors of Indonesia.<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»Expert Knowledge» _builder_version=»4.16″ _module_preset=»default» min_height=»609.2px» custom_margin=»-67px||-121px|||» custom_padding=»69px|||||» locked=»off» global_colors_info=»{}»][et_pb_row admin_label=»Row» _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.25.1″ _module_preset=»default» min_height=»45px» custom_padding=»||0px|||» global_colors_info=»{}»]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_2,1_2″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»1_2″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_icon font_icon=»||divi||400″ icon_color=»#001389″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][\/et_pb_icon][et_pb_text _builder_version=»4.25.1″ _module_preset=»default» global_colors_info=»{}»]<\/p>\n [\/et_pb_text][et_pb_text _builder_version=»4.17.4″ _module_preset=»default» global_colors_info=»{}»]<\/p>\n OTC and pharma market size, ex-factory<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=»1_2″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_icon font_icon=»||divi||400″ icon_color=»#001389″ _builder_version=»4.16″ _module_preset=»default» locked=»off» global_colors_info=»{}»][\/et_pb_icon][et_pb_text _builder_version=»4.17.4″ _module_preset=»default» global_colors_info=»{}»]<\/p>\n [\/et_pb_text][et_pb_text _builder_version=»4.16″ _module_preset=»default» locked=»off» global_colors_info=»{}»]<\/p>\n OTC and pharma market growth<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ admin_label=»Number Counter» _builder_version=»4.16″ _module_preset=»default» background_color=»#EEEEEE» locked=»off» global_colors_info=»{}»][et_pb_row _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_text _builder_version=»4.16″ _module_preset=»default» locked=»off» global_colors_info=»{}»]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_3,1_3,1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Total population» number=» 275 122 131″ percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» number_font_size=»64px» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Male\/Female» number=»1″ percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Population growth» number=»0.81%» percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=»1_3,1_3,1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Birth rate» number=»15.58\/1000″ percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» number_font_size=»64px» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Mortality rate» number=»6.74\/1000″ percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][et_pb_column type=»1_3″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_number_counter title=»Life expectancy» number=»72.82 years» percent_sign=»off» _builder_version=»4.16″ _module_preset=»default» number_text_color=»#0B0B7A» global_colors_info=»{}»][\/et_pb_number_counter][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=»1″ _builder_version=»4.16″ _module_preset=»default» locked=»off» global_colors_info=»{}»][et_pb_row _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_column type=»4_4″ _builder_version=»4.16″ _module_preset=»default» global_colors_info=»{}»][et_pb_cta title=»Interested in this market?» button_url=»https:\/\/www.chameleon-pharma.com\/about\/contacts\/» button_text=»Click here» _builder_version=»4.16″ _module_preset=»default» background_color=»#0B0B7A» global_colors_info=»{}»]<\/p>\n <\/span><\/p>\n We are ready to support you in\u00a0<\/span>Strategy, Marketing, Systematic International Company Partner Identification, Commercial Due Diligence, Business Development, Acquisition Search, Regulatory\u00a0projects,<\/span>\u00a0and more in order to ensure your growth.<\/span><\/p>\n<\/div>\n<\/div>\n [\/et_pb_cta][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Indonesia\u00a0Featured image: Photo by Sebastian Pena Lambarri on UnsplashIndonesia: a Self-Medication and Prescription Drugs market full of opportunities\u00a0 All indicators are green for the Indonesian Self-Medication and Prescription Drugs market. Continue reading to find out about the opportunities this market has to offer.\u00a0 Indonesia is the fourth most populous country in the world with 277 […]<\/p>\n","protected":false},"author":7,"featured_media":0,"parent":8782,"menu_order":39,"comment_status":"open","ping_status":"open","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"[caption id=\"attachment_873\" align=\"alignleft\" width=\"300\"]Indonesia: a Self-Medication and Prescription Drugs market full of opportunities\u00a0<\/strong><\/h2>\n
Product Registration in Indonesia<\/b><\/h3>\n
Improving healthcare<\/b><\/h3>\n
Regulations and restrictions in Indonesia<\/b><\/h3>\n
Increasing the Indonesian National Consumer Health and Pharma market<\/b><\/h3>\n
Drug donations to fight AIDS<\/b><\/h3>\n
Future Outlook<\/b><\/h3>\n
The Indonesian OTC and pharma market in 2040<\/h2>\n
USD 18,40 Billion <\/b><\/h3>\n
7-9<\/b>%<\/b><\/h3>\n
Indonesia in numbers<\/h2>\n
![\"Indonesia](\"https:\/\/www.chameleon-pharma.com\/wp-content\/uploads\/2014\/07\/Indonesia-TRIUMPH.jpg\")
Indonesia<\/a> by F Mira<\/a> with CC<\/a>[\/caption]\r\n\r\nWith a pop\u00adu\u00adla\u00adtion of 237 mil\u00adlion peo\u00adple, Indone\u00adsia is the fourth most pop\u00adu\u00adlated coun\u00adtry in the world<\/strong>. Within the Pharma mar\u00adket, it boasts a total annual growth of 13%, and the demand for qual\u00adity health\u00adcare prod\u00aducts is very high. From 2008 to 2013, Indonesia\u2019s expen\u00addi\u00adtures in the health\u00adcare sector increased from US $12.65 bil\u00adlion to approx\u00adi\u00admately US $26.93 bil\u00adlion.\r\n\r\nCon\u00adtrary to fore\u00adcasts made by numer\u00adous spe\u00adcial\u00adists, the lead\u00ading index IDX has tripled since 2009. The Indone\u00adsian pop\u00adu\u00adla\u00adtion is young, national debts are low, and the gov\u00adern\u00adment is ready to increase the flow of money within the health\u00adcare sec\u00adtor. The population\u2019s currently low con\u00adsump\u00adtion of Pharma prod\u00aducts coupled with its growing readi\u00adness to invest in health\u00adcare prod\u00aducts create an excellent potential for growth; the Indonesian Pharma mar\u00adket could eas\u00adily reach approx\u00adi\u00admately US $11.8 bil\u00adlion by 2015. Fur\u00adther\u00admore, the Indone\u00adsian gov\u00adern\u00adment is will\u00ading to favour part\u00adner\u00adships with for\u00adeign Pharma com\u00adpa\u00adnies, since the domes\u00adtic devel\u00adop\u00adment of health\u00adcare prod\u00aducts is still at a very low stan\u00addard.\r\n\r\n\r\n\r\n\r\n\r\n\r\nCPC Press Releases on Indonesia:<\/strong><\/h3>\r\nIndonesia: A lucrative market<\/a><\/strong>","_et_gb_content_width":"","footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-8794","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/pages\/8794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/comments?post=8794"}],"version-history":[{"count":15,"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/pages\/8794\/revisions"}],"predecessor-version":[{"id":22253,"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/pages\/8794\/revisions\/22253"}],"up":[{"embeddable":true,"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/pages\/8782"}],"wp:attachment":[{"href":"https:\/\/www.chameleon-pharma.com\/ru\/wp-json\/wp\/v2\/media?parent=8794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}